FDA Approves PHESGO — Genentech, Inc.

# FDA Approves Genentech's PHESGO as First Subcutaneous Combination HER2 Therapy Genentech's FDA approval of PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) marks a significant shift in HER2-positive breast cancer treatment, offering patients a subcutaneous alternative to intravenous infusions and positioning the company to capture market share in the competitive oncology space. The subcutaneous delivery mechanism could drive adoption by improving patient convenience and treatment adherence while reducing healthcare facility